A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | MicrobiomeTrials← Back to trialsNCT06745583
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-16Est. Completion: 2026-12
Enrollment target: 15 participants Locations- Taipei Veterans General Hospital, Taipei, Taiwan
- Tri-Service General Hospital, Taipei, Taiwan
Other microbiome trials you might be interested in
Mild Cognitive ImpairmentAlzheimer Disease
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults …
San Antonio, United StatesEst. completion Mar 5, 2026
Alzheimer s Disease
The goal of this clinical trial is to assess feasibility, safety, tolerability, and central nervous system target engage…
Multiple LocationsEst. completion Jun 1, 2029